EOLS (Evolus) LT-Debt-to-Total-Asset: 0.74 (As of Mar. 2026)

Evolus EOLS +2.22% 66 LT-Debt-to-Total-Asset is 0.74 as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 66/100 and a GF Value™ of $13.62 (Possible Value Trap). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Evolus's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.74.

Evolus's long-term debt to total assets ratio increased from Mar. 2025 (0.60) to Mar. 2026 (0.74). It may suggest that Evolus is progressively becoming more dependent on debt to grow their business.

Evolus (NAS:EOLS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Evolus LT-Debt-to-Total-Asset Related Terms

Evolus LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Evolus's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus LT-Debt-to-Total-Asset Chart

Evolus Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.29

0.41

0.66

0.55

0.68

Evolus Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.60	0.67	0.70	0.68	0.74

66GF Score

Evolus Inc EOLS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Evolus LT-Debt-to-Total-Asset Calculation

Evolus's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	152.467	/	225.868
	=	0.68

Evolus's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	162.352	/	220.646
	=	0.74

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.74 mean?

Evolus (EOLS) has a LT-Debt-to-Total-Asset of 0.74 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Evolus and its competitors.

Is Evolus' LT-Debt-to-Total-Asset too high?

Evolus' current LT-Debt-to-Total-Asset is 0.74. Overall, Evolus has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Evolus' LT-Debt-to-Total-Asset compare to NIKA and EBS?

Evolus' LT-Debt-to-Total-Asset of 0.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Evolus and its competitors. Evolus's current LT-Debt-to-Total-Asset is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evolus stock overvalued right now?

Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.62, compared to a current price of $6.90 — trading 49.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.74. Evolus' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Evolus (EOLS), the current LT-Debt-to-Total-Asset is 0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $6.90 is trading 49.3% below its estimated GF Value™ of $13.62. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

LT-Debt-to-Total-Asset: 0.74
GF Value™: $13.62 vs. price of $6.90 (49.3% below fair value)
GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolus Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NIKA EBS ELTP AQST TLRY ORGO TKNO AKBA SIGA IRWD XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges EVL:Germany

Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website https://www.evolus.com

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

66GF Score

Get the complete analysis for EOLS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.90

Price

$13.62

GF Value

View EOLS Analysis

See LT-Debt-to-Total-Asset data for all stocks →